about
Combination Approaches with Immune-Checkpoint Blockade in Cancer TherapySpecific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage InfiltrationMicroRNA-30a regulates cell proliferation and tumor growth of colorectal cancer by targeting CD73.The roles of CD73 in cancerCD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients.Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73).Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologistsTiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.Anti-CD73 in cancer immunotherapy: awakening new opportunities.Targeting CD73 in the tumor microenvironment with MEDI9447.MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer.High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors.Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.CD73-adenosine: a next-generation target in immuno-oncology.A preliminary study of the role of extracellular -5'- nucleotidase in breast cancer stem cells and epithelial-mesenchymal transition.Targeting A2 adenosine receptors in cancer.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.Role of adenosine signaling in the pathogenesis of breast cancer.Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Targeting immunosuppressive adenosine in cancer.Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside.Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: Self-amplifying immunosuppression in cancer.Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells.Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.Gut microbiome modulates efficacy of immune checkpoint inhibitors.Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.The Adenosine A₃ Receptor Regulates Differentiation of Glioblastoma Stem-Like Cells to Endothelial Cells under Hypoxia.
P2860
Q28066199-7DD71029-DB9A-4D01-999B-23DF3B794E0DQ28550667-BEB3B6C9-E068-4C92-9F9D-CD3AD6779AF2Q33630440-00725001-C766-44CF-A472-61CEF715C3DDQ34003164-20E03405-360D-44B6-8975-00C65C280760Q34473048-B33D16CB-24D8-45B8-A712-50EA0444BC26Q34680354-1ADEAAAA-2AE3-484F-93C4-20E757866D7DQ35090797-D6FE2C2E-2F3F-4F66-A6CE-D82341482003Q36343925-20B8BFB6-A2D0-4987-B2D3-D41028B7770CQ36430733-413FE853-99A2-46AD-AFBE-A0110BF4EECBQ36709157-4E27B959-C168-4450-8092-51F76D111979Q37224639-376EB200-4872-403F-8E53-2FFB3CE3881CQ37536763-65678DC3-DA69-42CA-892F-D6666BFE73C0Q37624627-AE9F7BC8-9EEF-464D-B2E6-6EB46C797C6EQ37636282-1BB55D30-0291-4D1C-A7C8-ABA5E5EE71EEQ38209586-0CF6CCD1-025A-418A-85F8-3C95A2A44DEFQ38711094-9557F6BD-BA7F-473B-B4C5-44CCBEC96343Q38743649-53CC730B-F1C8-4A95-8877-A5DBD04100FAQ39125149-FF95B708-E41B-47F0-80DD-EC602DC637D1Q39130451-818D68BD-01DC-4B70-9BBC-4F28011266D2Q39161005-3ADCF18F-89E8-407F-AE40-43156C69814FQ39224357-E22397B3-5E52-42EE-8622-5EC5CE0D2232Q41265675-82B3BC20-89FD-4B58-A62C-A7EA90C5A605Q46026307-C7653A0F-A09D-4B9F-BAAF-942CF8079FAFQ46047154-D233C9C3-9AB1-4723-91F2-DA5AC0056F11Q46140918-A2A69484-7EBF-47F8-98ED-713E4FBF2B84Q47104354-8022B419-DA11-468F-A882-37980469D699Q47395423-160766EC-D071-4F3C-A03E-0FC8BDA91A11Q51084411-02FEFCD5-B3AE-48DF-81F1-8F9863B28E76Q52323624-D5273B0E-905D-4B66-8EDB-B3B54F4F19E7Q52649982-3C191393-C55F-4D82-AF10-503A82E4FC10Q53037025-427D7142-2A3D-4A74-A9AC-7B45F5780A4AQ55001315-7E33E526-13AC-4C5D-A433-A9B460CECF58Q55240704-29733CA7-9BCA-4E95-93CD-3FF4B3F704E2Q55251496-7F764BE0-0DB3-4793-A456-515F4985DA93Q55309955-0A1B5D4C-71DF-4785-A1F8-FB423A21E92C
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Anti-CD73 therapy impairs tumor angiogenesis.
@en
Anti-CD73 therapy impairs tumor angiogenesis.
@nl
type
label
Anti-CD73 therapy impairs tumor angiogenesis.
@en
Anti-CD73 therapy impairs tumor angiogenesis.
@nl
prefLabel
Anti-CD73 therapy impairs tumor angiogenesis.
@en
Anti-CD73 therapy impairs tumor angiogenesis.
@nl
P2093
P2860
P356
P1476
Anti-CD73 therapy impairs tumor angiogenesis.
@en
P2093
Bertrand Allard
John Stagg
Kathleen Spring
Martin Turcotte
Sandra Pommey
P2860
P304
P356
10.1002/IJC.28456
P577
2013-09-18T00:00:00Z